Cybin Inc CYBN CYBN, a clinical-stage biopharmaceutical company on the frontier of developing psychedelic-based therapies, will provide updates on its ongoing clinical trials evaluating its proprietary deuterated molecules of a psilocybin analog known as CYB003, and CYB004 DMT at its virtual R&D Day webcast on Tuesday, February 28th at 10:00 Eastern Time.
CYB003 is the first-in-human trial evaluating how these differentiated psychedelic-based therapeutics can be used for the treatment of depression and anxiety disorders, which affect millions of people worldwide.
Register for the event here:
https://lifescievents.com/event/cybin-rd-day/
Learn more:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by Louis Reed on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
